Go Pro
NASDAQ:PMVP

PMV Pharmaceuticals Q1 2026 Earnings Report

PMV Pharmaceuticals logo
$1.33 -0.01 (-0.37%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.34 +0.00 (+0.38%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

PMV Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

PMV Pharmaceuticals Earnings Headlines

Elon’s AI Phone is coming
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP) is a clinical-stage precision oncology company focused on developing therapies that target cancer-driving genetic mutations. The company uses its proprietary research platform to discover and develop small-molecule medicines designed to restore the activity of mutated tumor-suppressor proteins.

PMV’s lead product candidate is rezatapopt (PC14586), an oral small-molecule therapy designed to reactivate the p53 protein when it carries the Y220C mutation. The candidate is being evaluated in patients with advanced solid tumors harboring this specific mutation, including through the company’s PYNNACLE clinical trial.

Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals focuses on oncology drug discovery and clinical development. Its programs are directed toward genetically defined cancers, with development activities primarily conducted in the United States and through clinical research networks.

View PMV Pharmaceuticals Profile